Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
TACT
Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell Carcinoma
- NCT05024266 ↗
- Unknown
- First Affiliated Hospital of Zhejiang University
- Deep
We haven't built an HCP commentary report on TACT (tislelizumab plus albumin paclitaxel plus carboplatin in stage IIIA-IIIB (N2) lung squamous cell carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on TACT so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 16 | |
| YouTube | 6 | |
| Podcasts | 4 |
The trial
ClinicalTrials.gov- Official title
- Tislelizumab Combined With Albumin Paclitaxel + Carboplatin as Neoadjuvant Therapy for Patients With Stage IIIA-IIIB (N2) Lung Squamous Cell Carcinoma: A Single-arm, Single-center, Exploratory Phase II Clinical Study
- Phase
- Phase 2
- Status
- Unknown
- Conditions
- Lung Squamous Cell Carcinoma; Neoadjuvant Therapy; Immunotherapy
- Interventions
- Tislelizumab
- Arms
- Tislelizumab + Albumin Paclitaxel + Carboplatin · Experimental
- Enrollment
- 30 (estimated)
- Primary outcomes
- Major Pathological Response (MPR)
- Incidence of Treatment-Emergent Adverse Events
- Sponsor
- First Affiliated Hospital of Zhejiang University
- Start
- Aug 1, 2021
- Primary completion
- Aug 31, 2022 (estimated)
- Results posted
- No
- Registry record
- NCT05024266 · updated Aug 27, 2021
Publications
linked from the registry- Shan J, Liu Z, Chen S, Du C, Li B, Ruan L, Kong M, Wang L, Du M, Shi S, Qiao G, Tian T, Tu Z. Optimizing perioperative treatment for potentially resectable stage III squamous cell lung carcinoma: promising results of a condensed four-cycle regimen with tislelizumaband chemotherapy. BMC Med. 2024 Jun 10;22(1):234. doi: 10.1186/s12916-024-03462-4. PubMed 38853265